Dostarlimab as a Miracle Drug: Rising Hope against Cancer Treatment
Immunotherapy is one of the four pillars of cancer treatment that has recently emerged as a beacon of hope for cancer patients. Certain immunotherapies, for example, immune checkpoint inhibitor therapy, monoclonal antibody therapy and chimeric antigen T-cell therapy have garnered extensive interest...
Main Authors: | Vanshikha Singh, Afsana Sheikh, Mohammed A. S. Abourehab, Prashant Kesharwani |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-08-01
|
Series: | Biosensors |
Subjects: | |
Online Access: | https://www.mdpi.com/2079-6374/12/8/617 |
Similar Items
-
Dostarlimab: A Review
by: Bárbara Costa, et al.
Published: (2022-07-01) -
An Exceptional Response to Dostarlimab in Mismatch Repair Deficient, Microsatellite Instability-High and Platinum Refractory Endometrial Cancer
by: Michele Bartoletti, et al.
Published: (2022-07-01) -
Dostarlimab: From preclinical investigation to drug approval and future directions
by: Carlo Maria Cicala, et al.
Published: (2023-01-01) -
A competitive ligand-binding assay for the detection of neutralizing antibodies against dostarlimab (TSR-042)
by: Xiaolong Tom Zhang, et al.
Published: (2021-11-01) -
The High-Resolution Structure Reveals Remarkable Similarity in PD-1 Binding of Cemiplimab and Dostarlimab, the FDA-Approved Antibodies for Cancer Immunotherapy
by: Tae-Jun Jeong, et al.
Published: (2022-12-01)